Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?

Houry Puzantian; Raymond Townsend; Shweta Bansal

doi:10.1111/jch.14898

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?

J Clin Hypertens (Greenwich). 2024 Nov 25. doi: 10.1111/jch.14898. Online ahead of print.

Authors

Houry Puzantian^{1

2}, Raymond Townsend³, Shweta Bansal⁴

Affiliations

¹ Hariri School of Nursing, American University of Beirut, Beirut, Lebanon.
² Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
³ Department of Medicine, Division of Renal, Electrolyte and Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁴ Department of Medicine, Division of Nephrology, University of Texas Health San Antonio, San Antonio, Texas, USA.

PMID: 39584490
DOI: 10.1111/jch.14898

Abstract

The obesity pandemic, with its associated comorbidities of hypertension and diabetes, constitutes a global public health issue. Importantly, there is an increasing prevalence of aldosterone excess related to obesity and resultant poor health outcomes. Nevertheless, the association between aldosterone and obesity still needs to be clarified. In this review, the authors discuss the role of white adipose tissue in linking obesity, aldosterone excess, and hypertension. The consequences of aldosterone excess in obesity are presented as genomic, non-genomic, and non-epithelial effects. Moreover, the authors emphasize the value of interference with aldosterone pathophysiology (as with mineralocorticoid antagonists) in obesity, thus reducing the adverse clinical impact of aldosterone in myocardial infarction, heart failure, kidney dysfunction, and associated mortality.

Keywords: aldosterone excess; mineralocorticoid; mineralocorticoid receptor; obesity.

Publication types

Review